Treatment with the AMDAR inhibitor (NBQX) and NMDAR inhibitor (D-AP5) effectively reduce the expression of NMDAR (NR1, NR2A/2B) and AMPAR (GluA1, GluA2) in PFC, respectively. D-AP5 (D-APV) is a selective and competitive NMDA receptor antagonist with a Kd of 1.4 μM. D-AP5 (D-APV) inhibits the glutamate binding site of NMDA receptors [1] [2].

So, the discoveries in the early 1980s of d -AP5 as a selective NMDA receptor antagonist and of its ability to block synaptic events and plasticity were a major breakthrough leading to an explosion of knowledge about this receptor subtype.

D-AP5 (D-APV) is a selective and competitive NMDA receptor antagonist with a Kd of 1.4 μM. D-AP5 (D-APV) inhibits the glutamate binding site of NMDA receptors.

D-2-Amino-5-phosphopentanoic acid (D-AP5) is an NMDA receptor antagonist that competitively inhibits the glutamate binding site of NMDA receptors with an IC 50 value of 30 µM. D-AP5 has been shown to cause damage in memory and learning processes and has the ability to trigger synaptic potentiation in the mature hippocampus

本系列实验研究了NMDA受体拮抗剂d -2-氨基-5-磷酸戊酸酯（D-AP5）是否能在与体内海马长期增强（LTP）损伤相当的剂量范围内诱导空间学习损伤。 利用微透析技术估计海马D-AP5的细胞外浓度，以比较这些损伤是否发生在与体外海马切片中损害LTP所需的浓度相似的浓度。 将D-AP5以一定浓度（0 ~ 50 mM）通过渗透微型泵长期注入大鼠侧脑室。 他们首先接受的训练是在一个开阔的水迷宫任务中找到并逃到一个隐藏的平台上。 行为学习结束后，他们被聚氨酯麻醉，并试图 …

D-AP5 (D-APV) 是一种选择性和竞争性NMDA 受体拮抗剂，Kd 为 1.4 μM。 D-AP5 抑制 NMDA 受体的谷氨酸结合位点。

争性抑制NMDA受体的谷氨酸结合位点。而D-AP5 是活性(-)- 立体异构体,其(+)- 异构体(L-AP5 )表现 出相当低的有效NMDA受体拮抗剂活性。NMDA 拮抗剂具有肌肉松弛的特性,已知能